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Abstract
The review aims to give an up to date understanding of the
mechanisms of apoptosis (programmed cell death), the meth-
ods of detecting apoptosis, in particular with regard to imaging
such changes non-invasively. Radioiodine (I-131) is a gamma
and beta emitting radionuclide and is commonplace in the treat-
ment of hyperthyroidism. I-131 therapy relies on the destruc-
tion of thyroid tissue by beta radiation, and such destruction is
proposed to be partly as a result of apoptosis. The review un-
dertakes to explore and provoke research into the mechanisms
of thyroid cell destruction by I-131, and whether such changes
are able to be detected or monitored. Current knowledge con-
cerning apoptosis in the thyroid gland in diseased states (in-
cluding cancer) are described. The clinical significance of mon-
itoring and modifying apoptosis are emphasized. Furthermore,
overt and late destruction of thyroid tissue following I-131 ther-
apy requires elaboration, and the relevance of detecting and
modifying thyroid cell apoptosis following I-131 are questioned.
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Introduction
Apoptosis (or programmed cell death) has been the subject
of intense interest and research recently. It is known to occur in all
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organs as a moderator of cellular growth, development death and
in many diseases. The study of apoptosis elaborates the mecha-
nisms of such cellular death, giving an insight as to how this pro-
cess can be regulated. The regulation of such processes would
ultimately result in prospects toward therapy in disease where
apoptosis plays a significant role. The ways of monitoring apop-
tosis give an indication of the extent of cellular death in a given
region. Of considerable interest is how cellular death changes
during tumour therapy and whether apoptosis is enhanced by
oncotherapy, giving a guide to the best treatment modality. The
ways to monitor apoptosis (invasive and non-invasive) in various
organs and tissues have been described, studied and are a hot
topic. Nuclear medicine gives one the possibility of non-invasive
monitoring and observation of cellular death. Nuclear medicine, due
to radiopharmaceuticals which bind to apoptotic markers (for e
xample annexin V labelled with technetium 99m) has become one
of the main methods of observing apoptosis in living organisms.
Radioiodine (I-131) therapy is commonplace in nuclear med-
icine. It is known that I-131 destroys thyroid tissue, and hence
reduces overactive thyroid tissue. What is not known, however, is
exactly how this tissue is destroyed and whether apoptotic changes
are initiated following I-131 therapy.
A study of cellular destruction following beta emitting radioio-
dine is the next step towards understanding how radioiodine dam-
ages thyroid tissue and whether apoptosis plays a significant role
during I-131 therapy. Can late hypothyroidism be attributed to an
excessive stimulation of programmed cell death? What are the
current possibilities and methods of monitoring apoptosis in var-
ious organs? What is the current focus toward modifying the mech-
anisms of programmed cellular death? Does knowledge of such
methods give an insight into possible additional therapy to mod-
ify cellular death following I-131, ultimately resulting in better prog-
noses? This review of apoptosis and the methods of monitoring it,
attempts to answer these questions.
The essence of apoptosis
Apoptosis appears to have been first discovered by Carl Vogt
in 1842 [1], and is an essential component during cellular devel-
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opment, embryogenesis, homeostasis, the  pathogenesis of many
diseases as a means of  removing excess, infected or damaged
cells by the activation of an extrinsic or intrinsic suicide program.
Such sequenced death is essential for proper embryonic devel-
opment, organogenesis, and in the regulation of cellular turnover,
as an integral component in most disease processes.
“Apoptosis” is derived from an ancient Greek word used to
describe the way petals fall off from flowers and trees and was the
term originally proposed during the “re-discovery” of programmed
cell death by Kerr, Wyllie and Currie in 1972 [2], which plays
a complementary but opposite role to mitosis in the regulation
of animal cell populations, including the worm, Caenorhabditis
elegans, where the biochemistry of apoptotic changes have been
extensively studied. There appear to be 14 caspases, 11 of which
are known  to be present in humans [3, 4, 12]. This form of cell
death contrasts with necrosis, which is a much more frequent type
of cellular death, being an uncontrolled process resulting from
acute injuries, resulting from factors such as radiation (of par-
ticular interest to nuclear medicine physicians), ischemia and
inflammation. Necrotic cells increase in volume and then rup-
ture, releasing their contents, inducing an inflammatory reac-
tion. These necrotic changes occur rapidly, and have a sharp
and swift nature which is extremely difficult to treat or prevent.
Oncosis differs from necrosis and refers to the pre-lethal chang-
es preceding necrosis, which are characterized by swelling, in
contrast to those of apoptosis, which are characterized by
shrinkage [4, 5].
Programmed cell death  is characterised by the maintenance
of an intact cellular membrane during the suicide process so as
to allow adjacent cells such as phagocytes  to engulf the dying
cell, without an inflammatory response. The maintenance of an
intact membrane is one of the features of apoptosis which is
of considerable importance and stresses that this process is es-
sentially intracellular. External membrane changes  are the cur-
rent focus of interest in identifying apoptosis using nuclear medi-
cine techniques. Cells undergoing apoptosis usually exhibit a char-
acteristic morphology by rapidly shrinking (as opposed to the swell-
ing during necrosis), chromatin condensation, nuclear fragmen-
tation, forming small apoptotic bodies, and endolytic cleavage
of DNA into small oligonucleosomal fragments which are then
phagocytosed  by macrophages [3, 4].
There are many signals which can trigger apoptosis, however
these signals to remove “unwanted or excessive” cells can be
broadly categorized as being either extra cellular or intracellular.
Extracellular signals may either suppress or promote apopto-
sis, and the same signals may promote survival in one cell type
and invoke the suicide program in others. For example, death
receptors that are members of the tumour necrosis factor recep-
tor (TNFR) family are present on cell membranes but have an in-
tracellular domain that awaits activation of an intrinsic apoptotic
pathway [6, 7]. Conversely, there are other factors, such as the
nerve growth factors (NGFs), that bind to cell surface receptors
and which act to prevent cell death [8, 9].
Intracellular signals, which also ultimately result in the activa-
tion of an intrinsic pathway can result from sub lethal damage
caused by factors such as hypoxia, ionizing radiation, chemo-
therapy, or viral infection [4, 10].
The mechanism of programmed cell death
Two general pathways can be separated. In the extrinsic, or
death receptor (DR) pathway, the apoptotic events are initiated
by engaging the tumour necrosis factor (TNF) family of receptors
(TNFRs), including TNFR1, Fas, DR 3-6. Upon ligand binding, or
when over expressed in cells, TNFR  family members aggregate,
resulting  in the recruitment of the adapter proteins,  fas associat-
ed death domain (FADD) and TNF-related apoptosis inducing
ligand (TRAIL) associated death domain (TRADD). These form
the death inducing signalling complex (DISC), which then recruits
procaspase-8 [7]. This allows proteolytic processing and activa-
tion of the receptor-associated procaspase-8 to active caspase 8,
thereby initiating the subsequent cascade  of additional process-
ing and activation of downstream effector caspases to activate
caspase 3 TRAIL or Apo2 ligand (TRAIL/Apo2L) is an apoptosis-
inducing member of the TNF gene superfamily [7, 12–15]. Unlike
TNF-a and fas ligand (FasL), TRAIL appears to specifically kill
transformed and cancer cells while leaving normal cells intact,
which is promising with regard to cancer therapy [16, 17].
The second pathway, which is known as the intrinsic or mitochon-
drial pathway mediates apoptosis induced by diverse stressful stimuli
(extrinsic factors) to the cell which cause DNA damage, leading to the
activation of p53 mediated mechanisms and  other stresses which
increase the activity of stress activated protein kinases (Fig. 1).
Figure 1. An illustration of the induction of apoptosis by extracellular and
mitochondrial pathways. Both pathways converge at caspase 3 activation.
55www.nmr.viamedica.pl
Antoni Sopotyk et al., Thyroid apoptosis and radioiodine
Reviews
In the mitochondrial pathway, death signals lead to mitochon-
drial permeability changes induced by cellular stresses and sub-
lethal insults (e.g. beta radiation, ischemia, inflammation), caus-
ing the release of pro-apoptotic factors. The factors released in-
clude the principal component cytochrome c, apoptosis inducing
factor (AIF), and second mitochondria-derived activator of caspase
(Smac/DIABLO).This interaction leads to the formation of the „ap-
optosome,” which is a complex composed of cytochrome c, apo-
ptosis protease activating factor (Apaf-1), and procaspase-9.
The formation of the apoptosome induces the activation
of caspase-9, which then processes and activates other caspas-
es to orchestrate the biochemical execution of cells [18].
The key regulatory proteins of mitochondria-mediated apop-
tosis are the Bcl-2 family of proteins, which are either anti-apop-
totic, and protect cells by inhibiting mitochondrial apoptosis, such
as Bcl-2 and Bcl-xl, or pro-apoptotic, which cause mitochondrial
apoptosis such as Bax and Bak. Their mechanism of action stills
requires elaboration, however, Bcl-2 and Bcl-xl appear to directly
or indirectly preserve the integrity of the outer mitochondrial mem-
brane, thus preventing cytochrome c release and mitochondria-
mediated cell death initiation, whereas the pro-apoptotic proteins
Bax and Bak promote the mitochondrial release of cytochrome c.
The mitochondrial permeability transition pore (MPTP) is known
to control the homeostasis of the mitochondrium and its permeablility
is regulated by Bcl-2 members. The MPTP is formed by the adenine
nucleotide transporter (ANT), the mitochondrial voltage dependent
anion channel (VDAC) and cyclophilin D. The MPTP participates in the
regulation of matrix Ca2+, pH, mitochondrial membrane potential (m),
and volume and functions as a Ca2+–, voltage–, pH–, and a redox
gated channel. Bax and Bak have been shown to associate with the
MPTP complex, leading to cytochrome c, inducing cell death.
Common ground between the pathways exist, in that both the
extrinsic and intrinsic pathways converge at caspase 3 activation.
Furthermore Bid, and it’s possible activation by caspase 8, and
p53 mediated activation of Bax may couple the stress activated
mitochondrial damage [7, 12–15, 19–21].
The role of apoptosis in diseases
and various conditions
Programmed cell death by nature, is present in all tissues and
organs, because life is finite and therefore apoptosis must occur
for us to grow old and die. There are, however, many disease states
where apoptosis is uncontrolled and excessive, or insufficient.
The areas of most interest to nuclear medicine and therapy are.
The central nervous system
Because the CNS is a site of intense apoptosis during its for-
mation during embryogenesis and appears to depend on survival
promoting genes such as Bcl-x for survival in adulthood, it may
be especially vulnerable to the derangement of apoptotic path-
ways [22]. Neurodegenerative diseases are, as the term suggests,
characterized by a degenerative process. These degenerative dis-
eases, which consist of disorders such as Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease and  amyotrophic later-
al sclerosis  are generally considered to be the result of neuronal
cell death in which apoptosis plays a significant role [23, 24].
Furthermore, interest has extended to the role apoptosis plays in
stroke and neonatal hypoxic brain injury [25–27].
The cardiovascular system
Apoptosis plays an essential role during the formation of the
heart and its septa. Anomalies in apoptosis may therefore con-
tribute toward illnesses arising from malformations such as con-
genital heart disease, and disorders of conduction pathways. Pro-
grammed cell death is believed to occur in the changes following
hypoxic injury and infarction such as reperfusion and remodelling
[28, 29]. Moreover, viral and autoimmune myocarditis, cardiomy-
opathies and vessel wall changes such as aneurism formation
and atherosclerotic plaque formation are generally considered to
be associated with programmed cell death [30].
Autoimmune disease
The immune system is the source of production of T and B
cells, which have an auto-reactive action, and are eliminated by
apoptosis. Therefore, it is postulated that unregulated excessive
apoptosis may be the cause of various autoimmune diseases that
are characterized by an excessive loss of normal or protective
cells, such as in multiple sclerosis, type-I diabetes mellitus, Hash-
imoto’s thyroiditis [31], Sjögrens syndrome, arthropathies, sys-
temic lupus erythematosus, rheumatic fever, Kawasaki’s disease
[30], and certain cancers such as melanoma [32]. Conversely, an
inappropriately low rate of apoptosis may promote the survival
and accumulation of abnormal cells that can give rise to tumour
formation and prolonged autoimmune stimulation such as in can-
cers and in Grave’s disease [33].
Organ transplantation and rejection
In rejected organ transplants, apoptotic cells are frequently
encountered, and apoptotic cell death may be part of the mecha-
nism of transplant rejection. High levels of expression of Fas ligand
on the allograft correlate with graft acceptance in some models of
organ transplantation. Furthermore, some of the immunosuppres-
sive drugs currently in clinical use might exert their activity at least
in part through effects on apoptotic pathways [34]. Moreover,
apoptosis occurring during rejection has been detected and lo-
calized in heart, lung and liver transplantation in vivo [35].
Oncology
Malignant tumours represent uncontrolled cellular growth,
which may be the result of insufficient or suppressed apoptosis.
Mutations of the Bcl-2 and p53 genes have been associated with
lymphomas. Additionally, mutations of the p53 gene are a com-
mon occurrence in most human cancers (55 to 70%) [36]. Tu-
mour reduction is known to be associated with apoptosis and
therefore a measure of the amount of apoptosis in a tumour in
response to therapy is of critical importance in assisting onco-
therapy [37, 38]. There is currently significant interest in localising
and evaluating programmed cell death by techniques involving
nuclear medicine, which would predict the chemo/ radiotherapy
sensitivity of a given tumour [39, 40].
Monitoring apoptosis by structure and
function. A need for non-invasive methods
There are numerous ways in which apoptosis can be detect-
ed. The most reliable methods are based on detecting the char-
acteristic morphological changes which require tissue sampling
(i.e. in vitro). However, due to the very important role apoptosis
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plays in disease, methods of detecting and monitoring apop-
tosis in the living organism (in vivo), without the need for tissue
sampling are being developed and are an area of intense re-
search.
Detecting apoptosis in vitro
The characteristic structural changes which are characteristic
of, and which define apoptosis, are most conclusively detected
by morphological viewing using electron microscopy, allowing the
early recognition of very subtle intracellular changes. An alterna-
tive to electron microscopy is light microscopy, which has a lower
resolution although is able to detect membrane blebbing and
apoptotic bodies.
TUNEL-Cleavage of genomic DNA during apoptosis may yield
double-stranded, low molecular weight DNA fragments (mono- and
oligonucleosomes) as well as single strand breaks (”nicks”) in high
molecular weight DNA. These DNA strand breaks can be identified
by labelling free 3´-OH terminals with modified nucleotides (such
as biotin or fluorescein) in an enzymatic reaction [41]. This tech-
nique relies on the DNA fragmentation that occurs during apopto-
sis and has become widespread in use; due to the fact that it is
simple and sensitive, although its sensitivity has been questioned
and has given rise to several variations of the technique [42].
Other methods for the detection of apoptosis include flow cy-
tometry, DNA laddering based on the fragmentation of genomic
DNA, Immunohistochemisty, and assays based on the expres-
sion of apoptotic factors, namely Fas, FasL, TRAIL, Bcl-2 and
caspases (in particular caspases 3 and 8) [43].
Detecting apoptosis in vivo
Magnetic resonance imaging. Apoptosis causes cellular
shrinkage, which consequently causes a change in water reso-
nance and diffusion, which MRI techniques are able to detect.
Such shrinkage is observed as a darkened area on an MRI study.
Changes in tissue water diffusion detected by diffusion weighted
MRI (DW-MRI) are considered to have a potential role in the in
vivo monitoring of apoptosis. For example, the volume reduction
of a tumour in response to chemotherapy can be measured, but
simple MRI would detect such changes too late to be clinically
of use. Furthermore, some tumours respond to certain chemo-
therapeutic agents by swelling, which would give a false result.
Magnetic resonance spectroscopy (MRS), based on the principle
of differences in the frequency of 1H, 31P, 13C is tissue depen-
dant  and has been shown to be of use in detecting apoptotic
changes [23, 25, 26].
A promising technique using MRI is using a protein as a con-
trast agent, namely the C2 domain of synaptotagmin I, which binds
to anionic phospholipids in cell membranes, such as phosphati-
dylserine (PS). PS lies on the cytoplasmic side of mammalian cells
and is absent on the surface of normal cells. This externalization
is an active process and requires the deactivation of translocase
and floppase, and the activation of scramblase, which are en-
zymes which maintain an asymmetric distribution of anionic and
cationic phospholipids. The externalization of PS occurs rapidly,
within 30–60 mins following the onset of apoptosis, before
blebbing, nuclear and cytoplasmic shrinkage. One drawback of
mapping PS, is that externalisation is not believed to be purely
specific for apoptosis [44, 45].
Using radioisotopes. Radioisotopes have, for a long while,
been used in determining possible areas of cell death-such radio-
isotopes include Tc99m-pyrophosphate, Indium 111-labelled anti-
myosin and Tc-99m-glucaric acid. All these radiotracers rely on the
loss of sarcolemma integrity in order to localize regions of necrosis
[46]. With respect to non-invasive imaging of myocardial damage,
it has recently been proposed that Tc-99m glucaric acid has only
an affinity for the oncotic myocardium, whereas indium antimyosin
has an affinity for both the oncotic and apoptotic myocardium [47].
PS, the most significant molecule known to change location follow-
ing cellular damage, has now become the main target for detecting
apoptosis [45].
Annexin V is a member of the calcium and phospholipid bind-
ing family of proteins which also has a vascular anticoagulant
activity. Annexin V is largely found on the cytosolic side of plasma
membranes and is known to have a high affinity (10-9M) for PS in
the presence of physiological concentrations of calcium. Hence,
due to this fact it is the main substance of concern for localizing
PS. Annexin V can be used to stain tissues and is a useful proper-
ty in the staining of apoptotic cells arising from the fact that it can
bind to many sites on cell surfaces, and therefore results in a very
intense signal. Due to its tracing abilities, annexin V was first used
successfully to identify thrombi in in-vitro models [48].
There have been several attempts to couple or modify anne-
xin V using various substrates. The labelling of annexin V with flu-
oroscein isothiocyanate has been used as a marker of apoptosis.
Biotin labelled annexin V has also been used to detect cellular
death and apoptotic changes [46].
The use of nuclear medicine techniques to demonstrate the
externalization of PS that occurs during apoptosis in vivo was first
used when Tc-99m-labelled annexin V, where the annexin V had
been conjugated with hydrazinonicotinamide (HYNIC) was used
in 3 animal models of apoptosis [35]. Since then, several studies
have been conducted with regards to tumours and chemothera-
py induced apoptosis using labelled annexin V [49–51].
There are many possibilities in using radiolabelled annexin V
— an additional role worthy of note is possible applications in the
monitoring of graft-host disease [30, 34].
Theoretically, annexin V can and has been used with other
radioisotopes to study and identify regions of cellular death, mainly
using I-123 and I-124 and 18F using PET [52–54].
Apoptosis in the thyroid
Whilst little is known concerning apoptosis of a normal thy-
roid, an extensive study has been carried out to elaborate apop-
totic pathways in autoimmune diseases such as Hashimoto’s and
Graves’ disease (GD) as well as in cancer. Increasing evidence
suggests that apoptosis plays an important role in the pathogen-
esis of autoimmune and proliferative thyroid diseases, and that
the apoptotic pathways involved are complex and highly regulat-
ed. It is known that thyrocytes from patients with Hashimoto’s thy-
roiditis are destroyed as a result of apoptosis, however it is still
uncertain whether such cellular death is caused by intrathyroidal
lymphocytes or the thyrocytes themselves [55, 56].
Autoimmune thyroid diseases such as GD and Hashimoto’s
thyroiditis have been associated with differential expression of Fas
and TRAIL receptor-mediated apoptosis and Fas is known to play
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a considerable role in thyroid disease [31]. Thyroid cell destruc-
tion characteristic of autoimmune thyroiditis can be seen as the
consequence of inappropriate expression of Fas or TRAIL death
pathway molecules and down-regulation of the apoptosis con-
trolling protein Bcl-2, which may be induced by cytokines released
locally by infiltrating lymphocytes. In contrast, GD thyrocytes are
protected from apoptotic death possibly by the anti-apoptotic
action of thyrotrophin receptor antibodies or soluble Fas and/or
the over expression of Fas ligand, which all create an anti-apop-
totic potential for the thyroid cells and favour apoptosis of the infil-
trating lymphocytes. Moreover, has been demonstrated that GD
thyrocytes express less Fas/FasL than HT thyrocytes, and that
GD thyrocytes express increased levels of anti apoptotic Bcl-2.
Thyroid hormones have been shown to induce apoptosis in
lymphocytes, reduce the expression of bcl-2, and induce the in-
tracellular formation of free radicals , whereas an excess of Iodine
is believed to induce Fas mediated apoptosis [57, 58]. An imbal-
ance between thyroid cell proliferation and cell death would ap-
pear to be a prerequisite for goitre formation or cancer develop-
ment and progression. In human thyroid goitre, Fas-mediated
apoptosis is suppressed, leading to thyroid cell hyperplasia. With
regard to malignancies of the thyroid, malignant cells may avoid
an immune response by over expressing Fas L and by inducing
apoptosis in the invading immune cells.
Radioiodine and apoptosis
— future possibilities
It is known that radiation induces apoptosis in various tissues
by causing sub lethal damage and activating the mitochondrial
pathway by the release of p53 in response to DNA damage. Radi-
ation is also thought to activate mitochondrial apoptosis by in-
duction of bax and down-regulation of anti-apoptotic genes, such
as bcl-2 are also thought to play a role. Recent concepts have
been introduced that radiation-induced apoptosis can be divided
into pre-mitotic and post-mitotic apoptosis, pre-mitotic apoptosis
being associated with a prompt activation of caspase 3, and post-
mitotic, which occurs after cell division, does not require such a rapid
activation of caspase 3 [59, 60].
Radioiodine (I-131) has been used for the treatment of hyper-
thyroidism since the 1940’s to treat conditions such as Graves’
disease and struma nodosa. Several long term studies have shown
I-131 therapy to be safe, with little, if any long term risks. Some
studies have shown a slight association with thyroid cancer, but
the reasoning for the association has been to put to question.
I-131 therapy has now replaced surgery as the non-conservative
method of treating hyperthyroidism, and is the preferred mode of
therapy for Grave’s disease in the U.S.
I-131 therapy relies on the fact that this isotope of iodine emits
beta radiation, and is selectively accumulated by hyper-functioning
thyroid tissue, where such beta emission induces cell death [61].
High doses which patients receive during I-131 therapy
immediately destroy thyroid tissue by simple necrosis. However,
it is reasonable to assume that neighbouring tissue which sur-
vives and receives sub lethal damage would undergo apoptotic
changes by activating mitochondrial apoptosis. Such tissue de-
struction by apoptosis would occur later, after the activation
of apoptotic pathways. Our department for treating hyperthyroid
patients monitors patients for at least 6 months following I-131
therapy, and up to 12 months, such monitoring being necessary
because experience has shown that renewed hyperthyroidism
or hypothyroidism may present relatively late.
A question which has been posed is why some patients have
such differing outcomes, considering that prior to therapy, they
had similar thyroid masses, scans, uptakes, biological half life, as
well as having received an identical dose? A hypothesis is that
late destruction of thyroid tissue, leading to late hypothyroidism is
caused by excessive apoptosis, stimulated by radioiodine.
Apoptosis is known to be present in thyroid disease states
but its role in healthy thyroid is still in question, whilst beta emi-
ssion is known to stimulate apoptosis. It is obvious that both healthy
and diseased thyroids exhibit apoptosis and such patients who
quickly become overtly hypothyroid may have a state of apopto-
sis in their thyroids, which is already excessive and vulnerable to
over stimulation by radioiodine.
The questions this short review poses are how exactly radio-
iodine affects apoptosis in the thyroid gland? To what degree does
radioiodine stimulate apoptosis and how can apoptosis be mo-
nitored or visualized to improve patient care?
Our department is currently working towards ways to assess the
degree of apoptosis in the thyroid in order to understand the effects
of radioiodine on thyroid tissue in order to answer these questions [61].
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